Biotechnology company and drug delivery platform innovator
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced additional
significant findings of TurboCBD(TM), the company’s proprietary,
DehydraTECH(TM) powered, cannabidiol (”CBD”) fortified hemp-oil capsule upon
completion of further data analyses from its 2018 randomized, placebo-controlled,
double-blinded European human clinical study. According to the update, a single
90mg dose of TurboCBD as compared to the same dose of generic CBD provided
evidence of lower blood pressure, higher blood flow to the brain, faster
delivery onset and larger quantities of CBD into the bloodstream. The study
revealed key metabolic and hemodynamic performance findings linked to
bioavailability enhancements. “The findings that Lexaria’s DehydraTECH(TM)
technology can enable superior cannabinoid delivery are unique in this
healthy-human clinical trial. However, the findings that the technology can
proffer a positive influence on blood pressure and perfusion to the brain are
truly remarkable,” Principal Investigator and Co-Director of the Centre for
Heart, Lung and Vascular Health, UBC Okanagan Campus, Kelowna, Canada Professor
Philip Ainslie, Ph.D. stated in the news release. “The potential benefits of
this approach, but over the acute and more chronic time periods, in more
middle-aged or elderly populations should now be prioritized. Establishing the
impact of CBD delivery on the health of the circulatory systems, including the
brain, could have major implications for the adjunct treatment of high blood
pressure and some neurological diseases.”
To view the full press release, visit http://ibn.fm/cJ6ce
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for utilization of its
DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs),nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
